Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies

NEUROSCIENCE LETTERS

卷:649

Review

Averill, Lynnette A.^1,2  Purohit, Prerana^1,2  Averill, Christopher L.^1,2  Boesl, Markus A.^1,2  Krystal, John H.^1,2  Abdallah, Chadi G.^1,2 

[1] US Dept Vet Affairs, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA

[2] Yale Univ, Sch Med, Dept Psychiat, 300 George St,Suite 901, New Haven, CT 06511 USA

关键词: Posttraumatic stress disorder (PTSD);    Glutamate;    Glutamine;    GABA;    NMDA;    Neurobiology;    Neurotransmission;    Novel therapeutics;    Treatment;    Ketamine;    D-Cycloserine;   

DOI  :  10.1016/j.neulet.2016.11.064

来源: Elsevier

【 摘 要 】

Posttraumatic stress disorder (PTSD) is a chronic and debilitating psychiatric disorder afflicting millions of individuals across the world. While the availability of robust pharmacologic interventions is quite lacking, our understanding of the putative neurobiological underpinnings of PTSD has significantly increased over the past two decades. Accumulating evidence demonstrates aberrant glutamatergic function in mood, anxiety, and trauma-related disorders and dysfunction in glutamate neurotransmission is increasingly considered a cardinal feature of stress-related psychiatric disorders including PTSD. As part of a PTSD Special Issue, this mini-review provides a concise discussion of (1) evidence of glutamatergic abnormalities in PTSD, with emphasis on human subjects data; (2) glutamate-modulating agents as potential alternative pharmacologic treatments for PTSD; and (3) selected gaps in the literature and related future directions. Published by Elsevier Ireland Ltd.

【 授权许可】

Free